Dividend-paying stocks are a traditional defensive play, while healthcare faces fewer trade and economic headwinds than most ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

Celonic Group, a Swiss-Based Quality CDMO, is integrating Merck’s Breez micro-bioreactor platform into its process ...

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...

FRANKFURT, March 6 (Xinhua) -- German science and technology giant Merck Group reported a return to growth in 2024, with net sales rising 0.8 percent to 21.16 billion euros (22.8 billion U.S. dollars) ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of ...

The company formerly known as Hipgnosis has officially been rebranded as Recognition Music Group following its acquisition by ...